Barclays PLC Roivant Sciences Ltd. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Barclays PLC holds 1,208,755 shares of ROIV stock, worth $24.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,208,755
Previous 2,114,867
42.84%
Holding current value
$24.5 Million
Previous $23.8 Million
23.27%
% of portfolio
0.0%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding ROIV
# of Institutions
376Shares Held
436MCall Options Held
6.03MPut Options Held
2.52M-
Morgan Stanley New York, NY44.3MShares$899 Million0.04% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X040.3MShares$818 Million4.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA38.8MShares$787 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$718 Million0.01% of portfolio
-
Qvt Financial LP New York, NY29.4MShares$596 Million36.4% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $14.3B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...